Connor Clark & Lunn Investment Management Ltd. Acquires New Holdings in Omeros Co. (NASDAQ:OMER)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 113,326 shares of the biopharmaceutical company's stock, valued at approximately $1,120,000. Connor Clark & Lunn Investment Management Ltd. owned 0.20% of Omeros as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Truvestments Capital LLC boosted its position in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares during the period. MML Investors Services LLC boosted its position in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 3,000 shares in the last quarter. US Bancorp DE purchased a new stake in Omeros in the fourth quarter worth $81,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Omeros in the fourth quarter worth $121,000. Institutional investors own 48.79% of the company's stock.

Omeros Stock Down 0.9 %

Shares of Omeros stock traded down $0.08 on Monday, reaching $9.02. The company's stock had a trading volume of 348,909 shares, compared to its average volume of 530,013. The company has a market capitalization of $522.71 million, a price-to-earnings ratio of -3.90 and a beta of 2.03. Omeros Co. has a 52 week low of $2.61 and a 52 week high of $13.60. The firm's fifty day simple moving average is $8.70 and its two-hundred day simple moving average is $7.37.

Remove Ads

Wall Street Analyst Weigh In

OMER has been the topic of a number of research reports. D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a report on Friday. Needham & Company LLC restated a "hold" rating on shares of Omeros in a report on Friday, January 17th. Finally, StockNews.com lowered shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.